A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Recruiting · Phase 3 · NCT06644781
Conditions: Esophageal Squamous Cell Carcinoma
At a glance
- Research payments reported, 2025
- $91,987
- U.S. investigators named
- 7
- Sites paid
- 11
- Planned or actual enrollment
- 510
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- Ifinatamab deruxtecan (drug), Docetaxel (drug), Paclitaxel (drug), Irinotecan hydrochloride (HCl) (drug)
- Dates
- Started 2025-03-27; completion 2029-11-01
- Results posted
- Not yet
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $91,987 in research payments for this study in 2025 (346 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David J. Park, M.D. Medical Oncology · Fullerton, CA
- Angela T. Alistar, MD Hematology & Oncology · Winston Salem, NC
- Yiwu Huang, MD Hematology & Oncology · Brooklyn, NY
- Donald S. Gravenor, M.D. Hematology & Oncology · Memphis, TN
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
- Latha S. Neerukonda, MD Medical Oncology · Fort Worth, TX
- Chao Yin, MD Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Henry Ford Health Hospital, MI $44,150
- Providence Medical Foundation $20,836
- Baptist Clinical Research Institute, Inc $16,620
- Maimonides Medical Center, NY $1,458
- Mayo Clinic Hospital, AZ $1,458
- Mayo Clinic Methodist Hospital $1,458
- Scri Oncology PArtners $1,440
- Morristown Medical Center, NJ $1,425
- Jps Health Network, TX $1,242
- Clinical Research Providence $1,090
- Virginia Cancer Specialists Fairfax $809
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.